Jaime Bartushak serves as Chief Financial Officer, Principal Financial Officer of the Company. He was appointed as Chief Financial Officer in November 2017. Previously, he was one of the founders and Chief Financial Officer of Leonard-Meron Biosciences, Inc., an acquired subsidiary of Citius,
As the Chief Financial Officer et Principal Financial Officer of Citius Pharmaceuticals Inc, the total compensation of Jaime Bartushak at Citius Pharmaceuticals Inc is $525,529. There are 4 executives at Citius Pharmaceuticals Inc getting paid more, with Myron Z. Holubiak having the highest compensation of $1,475,625.
Jaime Bartushak is 52, he's been the Chief Financial Officer et Principal Financial Officer of Citius Pharmaceuticals Inc since 2017. There are 13 older and no younger executives at Citius Pharmaceuticals Inc. The oldest executive at Citius Pharmaceuticals Inc is Suren Dutia, 77, who is the Independent Director.
Jaime's mailing address filed with the SEC is C/O CITIUS PHARMACEUTICALS, INC., 11 COMMERCE DRIVE, FIRST FLOOR, CRANFORD, NJ, 07016.
Over the last 9 years, insiders at Citius Pharmaceuticals Inc have traded over $0 worth of Citius Pharmaceuticals Inc stock and bought 13,825,289 units worth $15,819,221 . The most active insiders traders include Leonard L Mazur, Myron Z Holubiak et Dennis M Mcgrath. On average, Citius Pharmaceuticals Inc executives and independent directors trade stock every 207 days with the average trade being worth of $523,934. The most recent stock trade was executed by Eugene Myron Holuka on 13 March 2024, trading 2,415 units of CTXR stock currently worth $48.
citius pharmaceuticals, inc., a specialty pharmaceutical company, develops and commercializes critical care products. it primarily focuses on developing anti-infective, cancer care, prescription, and mesenchymal stem cell therapy products. the company is developing mino-lok, an antibiotic lock solution used to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in phase iii clinical trials; mino-wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; halo-lido, a corticosteroid-lidocaine topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; and novecite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome. citius pharmaceuticals, inc. was founded in 2007 and is headquartered in cranford, new jersey.
Citius Pharmaceuticals Inc executives and other stock owners filed with the SEC include: